Summary: Researchers have engineered a suite of adeno-associated virus (AAV) systems that deliver genes to specific neuron and glial subtypes in the brain and spinal cord with unprecedented precision. Driven by AI-selected DNA “enhancers” that act like cell-type-specific light switches, these vectors activate therapeutic or research genes only in designated cells. This approach reduces reliance on transgenic animals and enables detailed mapping, activation, or silencing of circuits at the cellular level.
Validated across multiple species and in human surgical tissue, the toolkit reaches previously elusive cell types implicated in disorders such as ALS, epilepsy, and Parkinson’s disease. By focusing on dysfunctional cells while sparing others, these gene-delivery tools provide a foundation for next-generation brain therapies that aim to treat underlying causes rather than only managing symptoms.
Key Facts:
- Cell-Specific Vectors: A broad collection of AAVs targets excitatory and inhibitory neurons, vascular cells, and spinal motor neurons with high selectivity.
- AI-Identified Enhancers: Machine-learning tools discover DNA enhancer sequences that drive gene expression in particular cell types, accelerating the design process.
- Accessible to Researchers: All vectors, standard operating procedures, and user guides are available through distribution centers to speed adoption and reproducibility.
Source: NIH
Overview
Research teams funded by the National Institutes of Health (NIH) have developed a versatile set of gene-delivery tools capable of targeting distinct neural cell types in the human brain and spinal cord with exceptional accuracy. These AAV-based systems represent an important advance toward precision gene therapies that could safely regulate abnormal neural activity at its source.
Unlike approaches that rely on genetically modified animals, this platform delivers genetic material directly into brain and spinal tissues of many species, and can even be applied to small tissue samples from human surgeries. That flexibility allows researchers to label fine cellular structures with fluorescent proteins, record activity, or activate and silence circuits that control behavior and cognition.
“Think of this platform as a delivery truck dropping tailored genetic packages into specific cellular neighborhoods of the brain and spinal cord,” said John Ngai, Director of the NIH’s Brain Research Through Advancing Innovative Neurotechnologies® (The BRAIN Initiative®). “These delivery systems enable access and manipulation of specific cells at a scale that was previously not possible.”
These tools use compact, engineered AAVs to ferry DNA payloads into targeted cells. They have been validated in living systems—an essential step for broad adoption. The published toolkit includes:
- Dozens of AAV constructs that selectively reach key brain cell types, including cortical excitatory neurons, diverse inhibitory interneurons, striatal cholinergic cells, vascular cells, and spinal motor neurons—the latter implicated in diseases such as amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy.
- Computational pipelines powered by artificial intelligence that mine multi-species genomic data to identify candidate enhancers—genetic “light switches” that drive expression in specific neural subtypes—reducing the time and effort required to find these regulatory elements.
Taken together, this collection of resources is designed to accelerate discovery and deepen understanding of human brain circuits. The toolkit enables access to cell types in regions such as the prefrontal cortex, which supports decision-making and complex human behaviors, and to pathways implicated in a range of neurological and neuropsychiatric disorders.
AAV-based gene therapies are already in clinical use for some conditions—for example, gene replacement therapy has transformed outcomes for children with certain spinal muscular atrophy subtypes. The new, more selective delivery systems lay the groundwork for therapies that precisely target affected cells in the brain, spinal cord, or cerebral blood vessels, potentially reducing side effects and improving efficacy.
The toolkit and related materials are distributed through research reagent centers, including Addgene. The accompanying publications provide standardized protocols, user guides, and best-practice recommendations to enable reproducible use across laboratories worldwide.
This work was supported by the NIH’s BRAIN Initiative. Launched less than four years ago as a coordinated, large-scale effort, the Armamentarium for Precision Brain Cell Access project brought together experts in molecular biology, neuroscience, and artificial intelligence to create reproducible methods for accessing specific cell types and circuits in experimental brain and spinal cord models.
Grants: UF1MH130701, UH3MH120096, U24MH133236, UF1MH128339, UM1MH130981, R01MH123620, U19MH114830, P510D010425, U420D011123, S10MH126994, UH3MH120094, UF1MH130881, F30DA053020, R01FD007478, U01AG076791, R35GM127102, RF1MH114126, UH3MH120095, RF1MH121274, R01MH113005, UH3MH120095.
About this genetic engineering research news
Author: NIH Office of Communications
Source: NIH
Contact: NIH Office of Communications – NIH
Image: The image is credited to Neuroscience News
Original Research: Open access. “An enhancer-AAV toolbox to target and manipulate distinct interneuron subtypes” by Elisabetta Furlanis et al. Cell
Abstract
An enhancer-AAV toolbox to target and manipulate distinct interneuron subtypes
Recent work has identified enhancers that, when included in recombinant AAV vectors, restrict transgene expression to particular neuronal populations. Despite these advances, viral tools for selectively accessing and manipulating defined neuronal subtypes remain limited.
In this study, researchers performed a systematic analysis of single-cell genomic datasets to identify candidate enhancers for telencephalic interneuron subtypes. They developed a set of enhancer-AAVs with high specificity for distinct cortical interneuron populations and for striatal cholinergic interneurons.
When combined with different effectors, these enhancers enable targeted expression of fluorescent reporters, activity indicators such as GCaMP, and optogenetic actuators, allowing researchers to label, monitor, and manipulate specific neuronal subtypes. The enhancer-AAV tools were validated across species, providing a robust toolkit to study neural circuits and to support the development of precise, cell-targeted therapies.